Investigational drug · Phase 2
HS-20110
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for CRC.
Phase 2Last checked: Nov 19, 2026Latest source record: May 1, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "HS-20110"
First trial start
2025
Dec 22, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HS-20110", any sponsor or status.
Conditions studied
As listed on its trial records.
- CRC
Largest trials
Live from ClinicalTrials.gov: studies naming "HS-20110" as an intervention, largest first.
Hansoh BioMedical R&D CompanyIndustry
NCT06892379 · 631 participants (planned) · Start Feb 26, 2025 · Primary completion Dec 31, 2026
Drug: HS-20110; HS-20110 and 2 more · For: Solid Tumors
Sites: Tamarac, Florida; Atlanta, Georgia; Fort Wayne, Indiana · 9 sites in all
- A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients.Recruiting
Hansoh BioMedical R&D CompanyIndustry
NCT07283367 · 502 participants (planned) · Start Dec 22, 2025 · Primary completion Dec 31, 2029
Drug: Cohort 1: HS-20110+ Bevacizumab+5-FU/leucovorin; Cohort 2: HS-20110+Bevacizumab+Oxaliplatin+5-FU/leucovorin and 1 more · For: CRC
Sites: Guangzhou, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for CRC
- GFH276Phase 25 trials
Genfleet Therapeutics (Shanghai) Inc. · RAS Mutation, Pancreatic Cancer, Non-small Cell Lung Cancer (NSCLC)
- RMC-9805Phase 23 trials
Revolution Medicines, Inc. · PDAC, Colorectal Cancer, CRC
- Tmod CAR T-cell TherapyA2B530, A2B694Phase 23 trials
A2 Biotherapeutics Inc. · Solid Tumor, Adult, Colorectal Cancer, Colorectal Adenocarcinoma
- OnvansertibPhase 22 trials
Cardiff Oncology · Metastatic Colorectal Cancer, CRC, KRAS/NRAS Mutation
- TUB-030Phase 21 trial
Gilead Sciences · Advanced Solid Tumors, HNSCC, SCLC
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.